Presence of an enamel matrix protein derivative on human teeth following periodontal surgery.
An enamel matrix protein derivative (EMD) has been successfully employed to restore fully functional periodontal ligament, cementum, and alveolar bone in patients with severe attachment loss. When applied to denuded root surfaces, EMD is believed to assemble into a matrix that locally stimulates regenerative responses in the surrounding tissues. Since wound healing and induction of regeneration are biological processes typically running from weeks to months after treatment, the EMD matrix must be present on the root surface over a biologically significant time period to be effective. So far, no studies have been done in humans on the persistence of EMD on the treated root surface. The aim of the present study was to investigate the persistence of the EMD-based matrix on periodontally involved human teeth treated surgically with EMD. Sixteen patients with one intrabony defect each around teeth scheduled for extraction due to advanced periodontitis were treated by means of access flap surgery with and without application of EMD. At 1, 2, 3, and 4 weeks postsurgery, the teeth were removed and processed for histology and immunohistochemistry. The slides were stained using a rabbit anti-enamel-matrix-derivative (anti-EMD) antibody and goat-antirabbit secondary antibodies labeled with horseradish peroxidase (HRP). Immunohistochemical evaluation demonstrated the presence of EMD on all test root surfaces during the entire observation period of 4 weeks. No EMD was detected on any of the control roots. The results demonstrate for the first time in humans that EMD is present on treated root surfaces for up to 4 weeks following periodontal surgery.
Sculean
Anton
A
Department of Periodontology and Conservative Dentistry, University of Saarland, 66421 Homburg, Germany. anton.sculean@gmx.de
Windisch
Péter
P
Keglevich
Tibor
T
Fabi
Beata
B
Lundgren
Eva
E
Lyngstadaas
Peter Staale
PS
D000328:Adult; D016301:Alveolar Bone Loss / Q000601:surgery; D000906:Antibodies; D002614:Chelating Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004396:Coloring Agents; D003746:Dental Enamel Proteins / Q000032:analysis / Q000627:therapeutic use*; D012534:Dental Scaling; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D008297:Male; D010518:Periodontitis / Q000601:surgery*; D016745:Root Planing; D013524:Surgical Flaps; D014092:Tooth Root / Q000473:pathology*; D014945:Wound Healing / Q000502:physiology
D000906:Antibodies; D002614:Chelating Agents; D004396:Coloring Agents; D003746:Dental Enamel Proteins; C109069:enamel matrix proteins; D004492:Edetic Acid